Consumer Goods & Retail Global On demand · 24-48h

Global Bio-manufacturing in Cosmetic Raw Materials Market Strategic Research Report

Global Bio-manufacturing in Cosmetic Raw Materials Market St…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Bio-manufacturing in Cosmetic Raw Materials Market
$3.08B2025
10.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Bio-fermentation Single Raw Materials, Bio-fermentation Mixed Raw Materials, Enzymatic Hydrolysis Raw Materials

By Application: Skincare, Makeup, Shampoo & Conditioner, Fragrance, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Evonik, Bloomage Biotechnology, Givaudan, Croda, Symrise AG, Lushang Freda Pharmaceutical, Kewpie Corporation, SILAB, TOYOBO, Jiangsu JLand Biotech, Contipro Inc., Jiangsu Chuangjian Medical Technology, Anhui Huaheng Biotechnology, Shandong Topscience Biotech, Shandong AWA Biopharm, Syensqo, Senruis Biotechnology, Technoble Co., Ltd., Wuhu Interferon Bio-products Industry Research Institute, TS-Biotech, HTL Biotechnology, INKOS, Shanxi Jinbo Bio-Pharmaceutical, Yili Chuanning Biotechnology, Zhihe Bio, Hubei Magic Health Technology, Vedan Biotechnology, Locus Ingredients, Luckerkong, GuangZhou MeiZhong Biological, Shandong Jincheng Biological Pharmaceutical, Kyowa Hakko Bio, GeneHarbor (Yuyao) Lifespan Health Technology, Shenzhen Siyomicro Bio-Tech, Holiferm, GeneIII, GSH Bio-Tech, Shenzhen Readline Biotech, Allied Carbon Solutions, Cornigs, XI`AN Sobeo Biotech, Hebei Nacol Biotechnology, EffePharm (Shanghai) Co, Jeneil Biotech, Jiangsu Youjie Biotechnology, Shenzhen Winkey Technology, Xuankai Biotechnology, Bontac Bio-Engineering, Giant Biogene Holding Co

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 213 pages
Market size 2025
$3.08B
Billion USD
Forecast CAGR
10.1%
2025-2032
Forecast 2032
$6B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Bio-manufacturing in Cosmetic Raw Materials market size is predicted to grow from US$ 3,076 million in 2025 to US$ 6,115 million in 2032; it is expected to grow at a CAGR of 10.1% from 2026 to 2032.

Biomanufacturing in the consumer chemicals industry refers to the introduction of biotechnology routes such as fermentation, enzymatic methods, biotransformation, and cell factories into the production of cosmetics and daily chemical raw materials. This replaces or supplements traditional animal-derived, plant-extracted, and petrochemical synthesis processes, resulting in more controllable molecular structures, more stable batch consistency, and a more traceable supply chain. It covers not only "functional active ingredients" (such as hyaluronic acid, recombinant collagen, peptides, ectoine, ergothioneine, etc.) but is also gradually extending to "material-type raw materials" (such as bio-surfactants, bio-based solvents, structured lipids/fermented oils, biodegradable additives, etc.), forming different application paths in specific scenarios such as skincare, hair care, household cleaning, fragrance, and oral/feminine hygiene. Essentially, biomanufacturing is not simply about "being more natural," but rather about using engineering methods to transform raw material production from an uncertain resource-dependent process into a designable, scalable, and auditable industrial system.

Biomanufacturing in cosmetic raw materials refers to the introduction of biotechnology routes such as fermentation, enzymatic methods, biotransformation, and cell factories into the production of cosmetic and daily chemical raw materials. This replaces or supplements traditional animal-derived, plant-extracted, and petrochemical synthesis processes, thereby achieving more controllable molecular structures, more stable batch consistency, and a more traceable supply chain. It covers not only "functional active ingredients" (such as hyaluronic acid, recombinant collagen, peptides, ectoine, ergothioneine, etc.) but is also gradually extending to "material-type raw materials" (such as bio-surfactants, bio-based solvents, structured lipids/fermented oils, biodegradable additives, etc.), forming different application paths in specific scenarios such as skincare, hair care, fragrance, and oral/feminine hygiene.

This report presents a comprehensive overview of the global Bio-manufacturing in Cosmetic Raw Materials market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Bio-fermentation Single Raw Materials
  • Bio-fermentation Mixed Raw Materials
  • Enzymatic Hydrolysis Raw Materials

Segment by Technology

  • Precision Fermentation
  • Biochemical Combination
  • Enzymatic Hydrolysis

Segment by Application

  • Skincare
  • Makeup
  • Shampoo & Conditioner
  • Fragrance
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Bio-manufacturing in Cosmetic Raw Materials market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Skincare, Makeup, Shampoo & Conditioner evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Bio-manufacturing in Cosmetic Raw Materials Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 10.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$3.08B
2025
Forecast
$6B
2032
CAGR
10.1%
2025–2032
Regions
5
global
Key companies
EvonikBloomage BiotechnologyGivaudanCrodaSymrise AGLushang Freda PharmaceuticalKewpie CorporationSILAB
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Bio-fermentation Single Raw MaterialsBio-fermentation Mixed Raw MaterialsEnzymatic Hydrolysis Raw Materials
By Application
SkincareMakeupShampoo & ConditionerFragranceOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Bio-fermentation Single Raw Materials
  • 3.1.3 Bio-fermentation Mixed Raw Materials
  • 3.1.4 Enzymatic Hydrolysis Raw Materials
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Skincare
  • 4.1.3 Makeup
  • 4.1.4 Shampoo & Conditioner
  • 4.1.5 Fragrance
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Evonik
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Bloomage Biotechnology
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Givaudan
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Croda
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Symrise AG
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Lushang Freda Pharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Kewpie Corporation
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 SILAB
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 TOYOBO
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Jiangsu JLand Biotech
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Contipro Inc.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Jiangsu Chuangjian Medical Technology
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Anhui Huaheng Biotechnology
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Shandong Topscience Biotech
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Shandong AWA Biopharm
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Syensqo
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Senruis Biotechnology
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Technoble Co., Ltd.
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Wuhu Interferon Bio-products Industry Research Institute
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 TS-Biotech
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 HTL Biotechnology
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 INKOS
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Shanxi Jinbo Bio-Pharmaceutical
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Yili Chuanning Biotechnology
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Zhihe Bio
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Hubei Magic Health Technology
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Vedan Biotechnology
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 Locus Ingredients
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 Luckerkong
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 GuangZhou MeiZhong Biological
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
  • 8.31 Shandong Jincheng Biological Pharmaceutical
  • 8.31.1 Company Overview
  • 8.31.2 Key Products & Segments
  • 8.31.3 Financial Performance (2023–2025)
  • 8.31.4 Business Strategy
  • 8.31.5 SWOT Analysis
  • 8.31.6 Strategic Implications (2026–2032)
  • 8.32 Kyowa Hakko Bio
  • 8.32.1 Company Overview
  • 8.32.2 Key Products & Segments
  • 8.32.3 Financial Performance (2023–2025)
  • 8.32.4 Business Strategy
  • 8.32.5 SWOT Analysis
  • 8.32.6 Strategic Implications (2026–2032)
  • 8.33 GeneHarbor (Yuyao) Lifespan Health Technology
  • 8.33.1 Company Overview
  • 8.33.2 Key Products & Segments
  • 8.33.3 Financial Performance (2023–2025)
  • 8.33.4 Business Strategy
  • 8.33.5 SWOT Analysis
  • 8.33.6 Strategic Implications (2026–2032)
  • 8.34 Shenzhen Siyomicro Bio-Tech
  • 8.34.1 Company Overview
  • 8.34.2 Key Products & Segments
  • 8.34.3 Financial Performance (2023–2025)
  • 8.34.4 Business Strategy
  • 8.34.5 SWOT Analysis
  • 8.34.6 Strategic Implications (2026–2032)
  • 8.35 Holiferm
  • 8.35.1 Company Overview
  • 8.35.2 Key Products & Segments
  • 8.35.3 Financial Performance (2023–2025)
  • 8.35.4 Business Strategy
  • 8.35.5 SWOT Analysis
  • 8.35.6 Strategic Implications (2026–2032)
  • 8.36 GeneIII
  • 8.36.1 Company Overview
  • 8.36.2 Key Products & Segments
  • 8.36.3 Financial Performance (2023–2025)
  • 8.36.4 Business Strategy
  • 8.36.5 SWOT Analysis
  • 8.36.6 Strategic Implications (2026–2032)
  • 8.37 GSH Bio-Tech
  • 8.37.1 Company Overview
  • 8.37.2 Key Products & Segments
  • 8.37.3 Financial Performance (2023–2025)
  • 8.37.4 Business Strategy
  • 8.37.5 SWOT Analysis
  • 8.37.6 Strategic Implications (2026–2032)
  • 8.38 Shenzhen Readline Biotech
  • 8.38.1 Company Overview
  • 8.38.2 Key Products & Segments
  • 8.38.3 Financial Performance (2023–2025)
  • 8.38.4 Business Strategy
  • 8.38.5 SWOT Analysis
  • 8.38.6 Strategic Implications (2026–2032)
  • 8.39 Allied Carbon Solutions
  • 8.39.1 Company Overview
  • 8.39.2 Key Products & Segments
  • 8.39.3 Financial Performance (2023–2025)
  • 8.39.4 Business Strategy
  • 8.39.5 SWOT Analysis
  • 8.39.6 Strategic Implications (2026–2032)
  • 8.40 Cornigs
  • 8.40.1 Company Overview
  • 8.40.2 Key Products & Segments
  • 8.40.3 Financial Performance (2023–2025)
  • 8.40.4 Business Strategy
  • 8.40.5 SWOT Analysis
  • 8.40.6 Strategic Implications (2026–2032)
  • 8.41 XI`AN Sobeo Biotech
  • 8.41.1 Company Overview
  • 8.41.2 Key Products & Segments
  • 8.41.3 Financial Performance (2023–2025)
  • 8.41.4 Business Strategy
  • 8.41.5 SWOT Analysis
  • 8.41.6 Strategic Implications (2026–2032)
  • 8.42 Hebei Nacol Biotechnology
  • 8.42.1 Company Overview
  • 8.42.2 Key Products & Segments
  • 8.42.3 Financial Performance (2023–2025)
  • 8.42.4 Business Strategy
  • 8.42.5 SWOT Analysis
  • 8.42.6 Strategic Implications (2026–2032)
  • 8.43 EffePharm (Shanghai) Co
  • 8.43.1 Company Overview
  • 8.43.2 Key Products & Segments
  • 8.43.3 Financial Performance (2023–2025)
  • 8.43.4 Business Strategy
  • 8.43.5 SWOT Analysis
  • 8.43.6 Strategic Implications (2026–2032)
  • 8.44 Jeneil Biotech
  • 8.44.1 Company Overview
  • 8.44.2 Key Products & Segments
  • 8.44.3 Financial Performance (2023–2025)
  • 8.44.4 Business Strategy
  • 8.44.5 SWOT Analysis
  • 8.44.6 Strategic Implications (2026–2032)
  • 8.45 Jiangsu Youjie Biotechnology
  • 8.45.1 Company Overview
  • 8.45.2 Key Products & Segments
  • 8.45.3 Financial Performance (2023–2025)
  • 8.45.4 Business Strategy
  • 8.45.5 SWOT Analysis
  • 8.45.6 Strategic Implications (2026–2032)
  • 8.46 Shenzhen Winkey Technology
  • 8.46.1 Company Overview
  • 8.46.2 Key Products & Segments
  • 8.46.3 Financial Performance (2023–2025)
  • 8.46.4 Business Strategy
  • 8.46.5 SWOT Analysis
  • 8.46.6 Strategic Implications (2026–2032)
  • 8.47 Xuankai Biotechnology
  • 8.47.1 Company Overview
  • 8.47.2 Key Products & Segments
  • 8.47.3 Financial Performance (2023–2025)
  • 8.47.4 Business Strategy
  • 8.47.5 SWOT Analysis
  • 8.47.6 Strategic Implications (2026–2032)
  • 8.48 Bontac Bio-Engineering
  • 8.48.1 Company Overview
  • 8.48.2 Key Products & Segments
  • 8.48.3 Financial Performance (2023–2025)
  • 8.48.4 Business Strategy
  • 8.48.5 SWOT Analysis
  • 8.48.6 Strategic Implications (2026–2032)
  • 8.49 Giant Biogene Holding Co
  • 8.49.1 Company Overview
  • 8.49.2 Key Products & Segments
  • 8.49.3 Financial Performance (2023–2025)
  • 8.49.4 Business Strategy
  • 8.49.5 SWOT Analysis
  • 8.49.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Bio-manufacturing in Cosmetic Raw Materials market?
The global Bio-manufacturing in Cosmetic Raw Materials market is estimated at US$ 3.08 billion in 2025 (base year) and is projected to reach US$ 6.12 billion by 2032.
How fast is the Bio-manufacturing in Cosmetic Raw Materials market expected to grow?
The market is expected to grow at a CAGR of 10.1% from 2026 to 2032, expanding from US$ 3.08 billion in 2025 to US$ 6.12 billion in 2032, roughly 2.0 times its base-year value.
What does the Bio-manufacturing in Cosmetic Raw Materials market cover?
Biomanufacturing in the consumer chemicals industry refers to the introduction of biotechnology routes such as fermentation, enzymatic methods, biotransformation, and cell factories into the production of cosmetics and daily chemical raw materials. This replaces or supplements traditional animal-derived, plant-extracted, and petrochemical synthesis processes, resulting in more controllable molecular structures, more stable batch consistency, and a more traceable supply chain.
What are the main segments of the Bio-manufacturing in Cosmetic Raw Materials market by type?
By type, the market is segmented into Bio-fermentation Single Raw Materials, Bio-fermentation Mixed Raw Materials and Enzymatic Hydrolysis Raw Materials.
Which applications drive demand in the Bio-manufacturing in Cosmetic Raw Materials market?
Key applications covered include Skincare, Makeup, Shampoo & Conditioner, Fragrance and Others.
Who are the key players in the Bio-manufacturing in Cosmetic Raw Materials market?
Key players profiled include Evonik, Bloomage Biotechnology, Givaudan, Croda, Symrise AG, Lushang Freda Pharmaceutical, Kewpie Corporation and SILAB, among 49 companies covered in total.
Which regions and countries are covered for Bio-manufacturing in Cosmetic Raw Materials?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Bio-manufacturing in Cosmetic Raw Materials market report?
The report is intended for manufacturers and solution providers, distributors and end users in Skincare, Makeup and Shampoo & Conditioner, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Bio-manufacturing in Cosmetic Raw Materials market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.